

Registry/ Observational study datawhat we can believe and what we can't believe!

Dr Ian Chau Consultant Medical Oncologist The Royal Marsden Hospital London & Surrey





Disclosure

- Advisory Board: Sanofi Oncology, Eli-Lilly, Bristol Meyers Squibb, Merck Serono, Gilead Science
- Research funding: Sanofi Oncology, Roche, Merck-Serono, Novartis
- Honorarium: Taiho, Pfizer, Amgen, Eli-Lilly, Bayer



Registry/ observation studies

- Observation cohort studies allows
 - access to innovation prior to marketing authorisation
 - further safety data collection in less stringent "real world" setting
 - combination with alternative standard of care treatment
 - much larger study sample sizes
- Limitations¹
 - Unable to randomly assign patient to treatment and control groups
 - Lead to imbalances between patients groups
 - Selection bias
 - Confounding variables correlating both the independent variable (treatment) and dependent variable (outcome); can be measured or unmeasured (such as patient or physician's choice)
 - Although various statistical methodologies to limit selection bias and confounding, this can never be fully controlled




Post authorisation studies

- Post authorisation safety study (PASS)
 - carried out after a medicine has been authorised
 - to identify, characterise or quantify a safety hazard
 - to confirm the safety profile of a medicine
 - to measure the effectiveness of risk-management measures
- Post authorisation efficacy study (PAES)
 - conducted within authorised therapeutic indication to complement available efficacy data in the light of well-reasoned scientific uncertainties on aspects of the evidence of benefits that should be, or can only be, addressed post-authorisation
 - may be initiated, managed or financed by a marketing authorisation holder (MAH) voluntarily
 - or pursuant to an obligation imposed by a competent authority




European Medicines Agency Accessed 4 December 2015

BRiTE study: continuing bevacizumab beyond disease progression



Ondansetron beyond disease progression




MO^{ASIA} 18-21 DECEMBER SINGAPORE Kopetz

SINGAPORE

2015


Kopetz et al. J Clin Oncol 2009

German AIO/Intergroup ML18147/TML trial design






Bennouna et al Lancet Oncol 2013





Bennouna et al Lancet Oncol 2013

Bevacizumab beyond first progression: Registry vs. RCT



Survival Beyond First Progression (months)

mOS beyond 1st progression BBP 19.2months No BBP 9.5 months HR: 0.49

SINGAPORE


18-21 DECEMBER

SINGAPORE

mOS beyond 1st progression BBP 11.2months No BBP 9.8 months HR: 0.81

> ¹Grothey et al. J Clin Oncol 2008; ²Bennouna et al Lancet Oncol 2013


Randomised controlled trials of regorafenib in mCRC



Regorafenib Placebo

mOS 6.4months 505 255 5.0 months HR: 0.77

Regorafenib Placebo





n

¹Grothey et al Lancet 2013; ²Li et al Lancet Oncol 2015

CONSIGN study

- Phase 3B study
- Purpose
 - To characterise safety of regorafenib
 - To allow patients with mCRC to receive regorafenib prior to market authorisation
- Population
 - Planned recruitment ~ 3000 patients
 - Actual recruitment = 2,872
 - Safety population = 2,864
 - Similar population to CORRECT (i.e. progression after biological therapy)
- PFS only efficacy variable (investigator-determined interval and assessed cf every 8 weeks in CORRECT and CONCUR)



Baseline characteristics of patients receiving regorafenib

Studies	CORRECT	CONCUR	CONSIGN
N	505	136	2,872
Median age	61	57.5	62
Male	62%	63%	59%
ECOG PS	52%/48%	26%/74%	47%/53%
0/1 KRAS mutation	54%	34%*	510/
Prior treatment	34%	54%	51%
1-2	27%	35%	26%
3	25%	24%	27%
≥4	49%	38%	46%

*29% had unknown KRAS status



Van Cutsem et al ESMO Asia 2015

Drug delivery of patients receiving regorafenib

Studies	CORRECT	CONCUR	CONSIGN
Ν	505	136	2,872
Median durat	ion of treatment 2.8 months	2.4 months	2.5 months
Mean percent	age of planned dose 78.9%	91%	75%



Van Cutsem et al ESMO Asia 2015


Adverse events of patients receiving regorafenib

Studies	CORRECT	CONCUR	CONSIGN
N	500	136	2,864
Any grade	93%	97%	91%
Grade ≥3	54%	54%	57%
Grade 5	<1%	1%	<1%
Grade 3 /4 toxicitie	es		
Hypertension	7%	11%	15%
Hand foot syndron	ne 17%	16%	14%
Fatigue	10%	3%	13%
Diarrhoea	7%	1%	5%
↑bilirubin	2%	6%	13%
↑AST	NR	6%	7%
↑ALT	NR	7%	6%
Anaemia	3%	2%	4%
Thrombocytopenia	a 3%	3%	2%
Neutropenia	NR	2%	1%



Van Cutsem et al ESMO Asia 2015

Progression free survival



SINGAPORE

2015

²Van Cutsem ESMO Asia 2015

Comments

- CONSIGN patient population more similar to CORRECT
- Safety broadly similar to pivotal CORRECT study
 - Incidences of AEs estimated with much greater precision
- Progression free survival similar to CORRECT study, but schedule of assessment imaging not predetermined
 - Why was overall survival not an efficacy outcome in this phase 3B study?
- Still cannot be clear about efficacy or safety in real world population



Patients' age on recruitment into phase III mCRC trials


Trials	Treatment arms	n	Median age in years (range)
FIRE 3 ¹	FOLFIRI + cetuximab	297	64 (38-79)
	FOLFIRI + bevaciuzmab	295	65 (27-76)
CALGB/SWOG	Chemo + cetuximab	578	59 (20-89)
80405 ²	Chemo + bevacizumab	559	59 (21-85)
TRIBE ³	FOLFIRI + bevacizumab	256	60 (29-75)
	FOLFOXIRI + bevacizum	nab 252	60.5 (29-75)
CORRECT ⁴	Regorafenib	505	61 (54-67)*
	Placebo	255	61 (54-68)*
RECOURSE ⁵	TAS-102	534	63 (27-82)
*IQR	Placebo	266	63 (27-82)
	SIA 18-21 DECEMBER SINGAPORE		nn et al Lancet Oncol 2014; ² Venook et al ASCO 2014 et al N Engl J Med 2014; ⁴ Grothey et al Lancet 2013

14; 3; ⁵Mayer et al N Engl J Med 2015

SEER data on CRC by age

Incidence of new CRC

CRC-related deaths






McCleary et al J Clin Oncol 2014


Multidisciplinary decision-making on palliative chemotherapy for mCRC

(b) Patients ≥70 years of age



- 157 MDT meetings over 3 years in a large teaching hospital in Utrecht, Netherlands
- 98% of young patients referred to oncologist to discuss chemotherapy vs.
 69% for the older (aged ≥70 years) patients

Multidisciplinary decision-making on chemotherapy for colorectal cancer






Hamaker et al J Geriatr Oncol 2015

French ThInDiT national cohort

Ν	Aged <75 3588	Aged ≥75 2724	р
Rx of mCRC			
Primary tumour resection	68%	57%	< 0.0001
Liver resection	17%	7%	< 0.0001
1 st line chemotherapy	85%	48%	< 0.0001
5-FU/Capecitabine mono	10%	30%	< 0.0001
Oxaliplatin-5FU	34%	31%	0.1
Irinotecan-5FU	6%	11%	< 0.00001
Irinotecan-Oxaliplatin-5FU	5%	2%	< 0.0001
Bevacizumab + chemo	35%	20%	< 0.0001
Cetuximab \pm chemo	9%	4%	< 0.0001
Median OS	22.3 months	8.4 months	




Evidence for treating mCRC in older patients








Evidence for treating mCRC in older patients





AVEX Study design




- ECOG PS 0-2
- Prior adjuvant chemotherapy allowed if completed >6 month before inclusion
- Not optimal candidates for a combination chemotherapy with irinotecan or oxaliplatin
- Key exclusion criteria
 - Prior chemotherapy for mCRC or prior adjuvant anti-VEGF treatment
 - Clinically significant cardiovascular disease
 - Current or recent use of aspirin (>325 mg/day) or other NSAID
 - Use of full-dose anticoagulants or thrombolytic agents




Baseline patient characteristics

	Cape + BEV (n=140)	Cape (n=140)
Female	40.0	40.0
	76 (70–87)	77 (70–87)
<75 years, %	39	33
\geq 75 years, %	61	67
0	50	43
1	41	48
2	7	8
Yes	32	19
Liver	63	68
Lung	36	41
Other	35	23
Liver only	37	39
Yes	74	64
Colon only	58	54
Rectum	31	25
Colon and rectum	11	19
	<75 years, % ≥75 years, % 0 1 2 Yes Liver Lung Other Liver only Yes Colon only Rectum	Image Image Female 40.0 76 (70–87) <75 years, %

2015






9.1 months

CAP 5.1 months



AVEX Overall survival





Subsequent therapies

Subsequent therapy (selected), %	Cape + BEV (n=140)	Cape (n=140)
Any additional treatment for malignancy	37	37
Fluoropyrimidine monotherapyl	17	18
Oxaliplatin-doublet	2	1
Irinotecan-doublet	6	3
Bevacizumab	6	8
Cetuximab	3	1
Panitumumab	1	4




Selected adverse events of special interest for bevacizumab and chemotherapy

	Bevacizumab plus capecitabine (n=134)				Capecitabine (n=136)			
	All grades	Grade 3	Grade 4	Grade 5	All grades	Grade 3	Grade 4	Grade 5
Selected adverse events of special in	nterest for bevac	izumab						
Bleeding/haemorrhage	34 (25%)	0	0	0	9 (7%)	0	0	1(1%)
Hypertension	26 (19%)	3 (2%)	0	0	7 (5%)	2 (1%)	0	0
Venous thromboembolic events	16 (12%)	3 (2%)	7 (5%)	1 (1%)	7 (5%)	4 (3%)	2 (1%)	0
Proteinuria	10 (7%)	2 (1%)	0	0	1(1%)	0	0	0
Arterial thromboembolic events	6 (4%)	2 (1%)	1(1%)	2 (1%)	3 (2%)	1 (1%)	0	0
Wound-healing complications	2 (1%)	0	0	0	0	0	0	0
Pulmonary haemorrhage or haemoptysis	1(1%)	0	0	0	1(1%)	1(1%)	0	0
Congestive heart failure	0	0	0	0	1(1%)	0	0	1 (1%)
Fistulae	1(1%)	0	0	0	0	0	0	0
Gastrointestinal perforation	1(1%)	0	0	0	0	0	0	0
Reversible posterior leukoencephalopathy syndrome	0	0	0	0	0	0	0	0
Selected adverse events of special in	nterest for cheme	otherapy*						
Hand-foot syndrome	66 (49%)	21 (16%)	0	0	54 (40%)	9 (7%)	0	0
Diarrhoea	54 (40%)	8 (6%)	1 (1%)	0	48 (35%)	7 (5%)	2 (1%)	0
Asthenia	30 (22%)	6 (4%)	1 (1%)	0	22 (16%)	4 (3%)	1 (1%)	0
Fatigue	32 (24%)	4 (3%)	1(1%)	0	37 (27%)	1(1%)	0	0
Nausea	32 (24%)	1(1%)	0	0	37 (27%)	0	0	0
Vomiting	28 (21%)	3 (2%)	0	0	16 (12%)	2 (1%)	0	0
Stomatitis	20 (15%)	0	0	0	11 (8%)	1 (1%)	0	0
Neutropenia	7 (5%)	0	1 (188)	0	2 (1%)	1 (1%)	0	0



SINGAPORE

Evidence for treating mCRC in older patients





Prospective studies of first line bevacizumabcontaining regimens in older population

Author	Country	n	Treatment	Median age	PS2	ORR	mPFS	mOS
Naeim et al ¹	USA	45	CAP + Be	v 79	62%	35.5%	6.87	12.7
Yoshida et al ²	Japan	56	S-1 + Bev	75	0%	43%	9.9	25
Vamvakas et al	³ Greece	48	CAPOX +	Bev 76	8.3	% 46.8%	6 7.9	20.1
Feliu et al ⁴	Spain	68	CAPOX +	Bev 75.6	0%	45.6%	11.1	20.4

¹Naeim et al J Geriatr Oncol 2013; ²Yoshida et al Eur J Cancer 2015; ³Vamvakas et al BMC Cancer 2014; ⁴Feliu et al Br J Cancer 2014




Toxicities

- Toxicities in these four prospective studies in the elderly appeared to be comparable to other RCTs involving all age groups.
- Grade 3 toxicities are mainly in diarrhoea and fatigue
- BEV-related adverse events did not appear to be more pronounced than expected



Evidence for treating mCRC in older patients







Pooled analysis of registry data

- Five phase 4/ observational cohort studies
- N=7,688
- Allowed analyses of the very young (aged <25) and the very old (aged >85) both under-represented in RCTs
- Somewhat worse OS in the very young (n=13) and the very old (n=67), although small sample sizes means large 95% confidence intervals; thus overlapped with other age groups
- PFS similar trend in the very young, but not the very old
- Toxicities not quantified in these extreme age group due to small sample sizes, but probably safe in the elderly



BUT: Cautionary notes to generalise results from these registry data to routine clinical practice

- Exclusion criteria of BEAT:
 - Uncontrolled hypertension;
 - clinically significant cardiovascular disease,
 - haemorrhagic diathesis or coagulopathy;
 - use of full-dose anticoagulants or thrombolytics;
 - serious non-healing wounds or ulcers and treatment with aspirin (>325 mg/day) or other medications predisposing to GI ulceration
- However BRiTE and ARIES did not have such exclusion criteria
- Other studies encouraged clinicians to treat patients that fulfil the criteria of bevacizumab treatment based on the summary of product characteristics (SPC)
 - SPC cautions the use of bevacizumab in all the above situation



Conclusions

- What we can believe
 - Safety of regorafenib was generally in line with what observed in RCTs
 - 1 incidence of hypertension and hyperbilirubinaemia with regorafenib in CONSIGN compared to RCT
 - Bevacizumab could be combined with different chemotherapy backbones in the elderly
- What we can't believe
 - Missing safety data on less common VEGF-related side effects (fistula/fissures, reversible posterior leucoencephalopathy syndrome)
 - Selection bias in patients entering into observation studies
 - Comparative data are at best hypothesis-generating
 - Efficacy of bevacizumab in the very elderly age groups care should be exercised when registry data go beyond their original purpose and attempt to answer effectiveness questions



Acknowledgement

National Health Service funding to the National Institute for Health Research Biomedical Research Centre



